newsfilter
← Latest News
ACCESS Newswire·

CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study

- CID-103 is a potential best-in-class, clinical stage anti-CD38 monoclonal antibody- Safety profile observed in first four dose cohorts supports continued development- No serious adverse events or dose-limiting